• Login
    View Item 
    •   UMB Digital Archive
    • School, Graduate
    • Theses and Dissertations All Schools
    • View Item
    •   UMB Digital Archive
    • School, Graduate
    • Theses and Dissertations All Schools
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Identification and Characterization of GTP-binding Inhibitors of LRRK2

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Thomas_umaryland_0373D_10790.pdf
    Size:
    2.577Mb
    Format:
    PDF
    Download
    Author
    Thomas, Joseph Michael
    Advisor
    Smith, Wanli W.
    Date
    2016
    Type
    dissertation
    
    Metadata
    Show full item record
    Abstract
    Parkinson's disease (PD) is one of the most common neurodegenerative disorders in aged adults, resulting from the loss of dopaminergic neurons in the substantia nigra and the accumulation of Lewy body aggregates in the brain. Currently there are no disease altering treatments for PD. Mutations in Leucine-rich repeat kinase 2 (LRRK2) are the most common contributors to both familial and sporadic PD cases, however the exact physiological role of LRRK2 is currently unclear. As a large protein (286 kDa) with both GTPase and kinase activities, LRRK2 represents a tractable target for PD intervention. The work in this dissertation focuses on the identification and characterization of GTP-binding inhibitors of LRRK2. Moreover, I further investigate the biopathological roles of LRRK2 on neural transport functions underlying neurdegeneration and test the neuroprotective effects of LRRK2 GTP-binding inhibitors. I discovered that the novel compound, 68, inhibits GTP-binding as well as kinase activities in LRRK2, and that optimized compound FX2149, a new analog of 68, shows significant improvements in blood brain barrier (BBB) penetration and in vivo efficacy in LRRK2 mutant brains. Furthermore, I demonstrate that the LRRK2 GTPase domain mutation, R1441C, impairs neural transport functions, however these impairments can be attenuated through treatment with our GTP-binding inhibitors. Lastly, I show that our GTP-binding inhibitors increase LRRK2 ubiquitination, with a preferential increase in atypical ubiquitin linkages. This work provides further insight into LRRK2 functions in the pathobiology of PD, as well as provides evidence for the applicability of GTP-binding inhibitors as pharmacological tools and potential therapeutic agents in the treatment of PD.
    Description
    University of Maryland, Baltimore. Pharmaceutical Sciences. Ph.D. 2016
    Keyword
    GTP-binding inhibitors
    LRRK2
    Leucine-Rich Repeat Serine-Threonine Protein Kinase-1
    Parkinson Disease
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/6281
    Collections
    Theses and Dissertations School of Pharmacy
    Theses and Dissertations All Schools

    entitlement

     
    DSpace software (copyright © 2002 - 2019)  DuraSpace
    Quick Guide | Policies | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.